Acta Neuropathologica

, 111:483

Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression

  • Kazuhiko Mishima
  • Yukinari Kato
  • Mika Kato Kaneko
  • Ryo Nishikawa
  • Takanori Hirose
  • Masao Matsutani
Original Paper

Abstract

Podoplanin (aggrus) is a mucin-like transmembrane sialoglycoprotein that is expressed on lymphatic endothelial cells. Podoplanin is putatively involved in cancer cell migration, invasion, metastasis, and malignant progression and may be involved in platelet aggregation. Previously, we showed upregulated expression of podoplanin in central nervous system (CNS) germinomas, but not in non-germinomatous germ cell tumors, except for parts of immature teratomas in limited numbers. However, little information exists about its role in CNS astrocytic tumors. In this study, 188 astrocytic tumors (30 diffuse astrocytomas, 43 anaplastic astrocytomas, and 115 glioblastomas) were investigated using immunohistochemistry with an anti-podoplanin antibody, YM-1. In 11 of 43 anaplastic astrocytomas (25.6%) and in 54 of 115 glioblastomas (47.0%), podoplanin was expressed on the surface of anaplastic astrocytoma cells and glioblastoma cells, especially around necrotic areas and proliferating endothelial cells. However, the surrounding brain parenchyma was not stained by YM-1. On the other hand, podoplanin expression was not observed in diffuse astrocytoma (0/30: 0%). Furthermore, we investigated the expression of podoplanin using quantitative real-time PCR and Western blot analysis in 54 frozen astrocytic tumors (6 diffuse astrocytomas, 14 anaplastic astrocytomas, and 34 glioblastomas). Podoplanin mRNA and protein expression were markedly higher in glioblastomas than in anaplastic astrocytomas. These data suggest that podoplanin expression might be associated with malignancy of astrocytic tumors.

Keywords

Podoplanin Astrocytoma Glioblastoma YM-1 

References

  1. 1.
    Breiteneder-Geleff S, Soleiman A, Kowalski H, Horvat R, Amann G, Kriehuber E, Diem K, Weninger W, Tschachler E, Alitalo K, Kerjaschki D (1999) Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 154:385–394PubMedGoogle Scholar
  2. 2.
    DeAngelis LM (2001) Brain tumors. N Engl J Med 344:114–123PubMedCrossRefGoogle Scholar
  3. 3.
    Geiger KD, Stoldt P, Schlote W, Derouiche A (2000) Ezrin immunoreactivity is associated with increasing malignancy of astrocytic tumors but is absent in oligodendrogliomas. Am J Pathol 157:1785–1793PubMedGoogle Scholar
  4. 4.
    Giese A, Bjerkvig R, Berens ME, Westphal M (2003) Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 21:1624–1636PubMedCrossRefGoogle Scholar
  5. 5.
    Honn KV, Tang DG, Crissman JD (1992) Platelets and cancer metastasis: a causal relationship? Cancer Metastasis Rev 11:325–351PubMedCrossRefGoogle Scholar
  6. 6.
    Kaneko M, Kato Y, Kunita A, Fujita N, Tsuruo T, Osawa M (2004) Functional sialylated O-glycan to platelet aggregation on Aggrus (T1alpha/podoplanin) molecules expressed in Chinese Hamster Ovary cells. J Biol Chem 279:38838–38843PubMedCrossRefGoogle Scholar
  7. 7.
    Kato Y, Fujita N, Kunita A, Sato S, Kaneko M, Osawa M, Tsuruo T (2003) Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors. J Biol Chem 278:51599–51605PubMedCrossRefGoogle Scholar
  8. 8.
    Kato Y, Sasagawa I, Kaneko M, Osawa M, Fujita N, Tsuruo T (2004) Aggrus: a diagnostic marker that distinguishes seminoma from embryonal carcinoma in testicular germ cell tumors. Oncogene 23:8552–8556PubMedCrossRefGoogle Scholar
  9. 9.
    Kato Y, Kaneko M, Sata M, Fujita N, Tsuruo T, Osawa M (2005) Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma. Tumor Biol 26:195–200CrossRefGoogle Scholar
  10. 10.
    Kleihues P, Ohgaki H (1999) Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro-oncology 1:44–51PubMedCrossRefGoogle Scholar
  11. 11.
    Kleihues P, Burger PC, Collins VP, Newcomb EW, Ohgaki H, Cavenee WK (2000) Astrocytic tumors. Glioblastoma. In: Kleihues P, Cavenee WK (eds) Pathology and genetics of tumours of the nervous system. International Agency for Research on Cancer Press, Lyons, France, pp 29–39Google Scholar
  12. 12.
    Martin-Villar E, Scholl FG, Gamallo C, Yurrita MM, Munoz-Guerra M, Cruces J, Quintanilla M (2005) Characterization of human PA2.26 antigen (T1alpha-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas. Int J Cancer 113:899–910PubMedCrossRefGoogle Scholar
  13. 13.
    Mishima K, Kato Y, Kaneko KM, Nakazawa Y, Kunita A, Fujita N, Tsuruo T, Nishikawa R, Hirose T, Matsutani M (2006) Podoplanin expression in primary central nervous system germ cell tumors: a useful histological marker for the diagnosis of germinoma. Acta Neuropathol (Berl) (in press)Google Scholar
  14. 14.
    Ordonez NG (2005) D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum Pathol 36:372–380PubMedCrossRefGoogle Scholar
  15. 15.
    Roy S, Chu A, Trojanowski JQ, Zhang PJ (2005) D2-40, a novel monoclonal antibody against the M2A antigen as a marker to distinguish hemangioblastomas from renal cell carcinomas. Acta Neuropathol (Berl) 109:497–502CrossRefGoogle Scholar
  16. 16.
    Schacht V, Ramirez MI, Hong YK, Hirakawa S, Feng D, Harvey N, Williams M, Dvorak AM, Dvorak HF, Oliver G, Detmar M (2003) T1alpha/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. EMBO J 22:3546–3556PubMedCrossRefGoogle Scholar
  17. 17.
    Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong YK, Detmar M (2005) Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol 166:913–921PubMedGoogle Scholar
  18. 18.
    Scholl FG, Gamallo C, Vilaro S, Quintanilla M (1999) Identification of PA2.26 antigen as a novel cell-surface mucin-type glycoprotein that induces plasma membrane extensions and increased motility in keratinocytes. J Cell Sci 112:4601–4613PubMedGoogle Scholar
  19. 19.
    Scholl FG, Gamallo C, Quintanilla M (2000) Ectopic expression of PA2.26 antigen in epidermal keratinocytes leads to destabilization of adherens junctions and malignant progression. Lab Invest 80:1749–1759PubMedCrossRefGoogle Scholar
  20. 20.
    Shibahara J, Kashima T, Kikuchi Y, Kunita A, Fukayama M (2006) Podoplanin is expressed in subsets of tumors of the central nervous system. Virchows Arch (in press)Google Scholar
  21. 21.
    Sugimoto Y, Watanabe M, Oh-hara T, Sato S, Isoe T, Tsuruo T (1991) Suppression of experimental lung colonization of a metastatic variant of murine colon adenocarcinoma 26 by a monoclonal antibody 8F11 inhibiting tumor cell-induced platelet aggregation. Cancer Res 51:921–925PubMedGoogle Scholar
  22. 22.
    Tsuruo T, Yamori T, Naganuma K, Tsukagoshi S, Sakurai Y (1983) Characterization of metastatic clones derived from a metastatic variant of mouse colon adenocarcinoma 26. Cancer Res 43:5437–5442PubMedGoogle Scholar
  23. 23.
    Tynninen O, Carpen O, Jaaskelainen J, Paavonen T, Paetau A (2004) Ezrin expression in tissue microarray of primary and recurrent gliomas. Neuropathol Appl Neurobiol 30:472–477PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Kazuhiko Mishima
    • 1
  • Yukinari Kato
    • 2
  • Mika Kato Kaneko
    • 2
  • Ryo Nishikawa
    • 1
  • Takanori Hirose
    • 3
  • Masao Matsutani
    • 1
  1. 1.Department of NeurosurgerySaitama Medical SchoolSaitamaJapan
  2. 2.Research Center for GlycoscienceNational Institute of Advanced Industrial Science and Technology (AIST), Open Space Laboratory C-2IbarakiJapan
  3. 3.Department of PathologySaitama Medical SchoolSaitamaJapan

Personalised recommendations